Equity Details
Price & Market Data
Price: $4.13
Daily Change: -$0.10 / 2.42%
Daily Range: $4.10 - $4.29
Market Cap: $516,854,496
Daily Volume: 892,914
Performance Metrics
1 Week: -10.24%
1 Month: -4.03%
3 Months: 5.98%
6 Months: -24.82%
1 Year: 84.29%
YTD: -36.31%
About Aquestive Therapeutics, Inc. (AQST)
Key metrics for Aquestive Therapeutics, Inc. (AQST). Current price: 4.13, daily change: -$0.10 / 2.42%. Market cap: 516,854,496. Performance across all periods for quick analysis.
Company Details
Employees: 147
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
